Biotinylated Human BTLA (31-150) (M105V, G138S, V148M) Protein, Fc,Avitag™ (MALS verified)

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 41.9 kDa. The protein migrates as 53-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Human HVEM, Mouse IgG2a Fc Tag, low endotoxin at 5 μg/mL (100 μL/well) can bind Biotinylated Human BTLA (31-150) (M105V, G138S, V148M), Fc,Avitag (Cat. No. BTA-H82F5) with a linear range of 0.001-0.313 μg/mL (QC tested).